Infectious complications in XXXX with @entity1582 treated with new drug combinations containing @entity2816 .

@entity1 @entity55 @entity326 @entity5 @entity2816 @entity1582 @entity281 @entity1398
The literature provides scant data concerning infectious complications and their effect on the outcome of @entity1 with @entity1582 ( @entity1582 ) treated with new drug combinations. Despite no substantial myelotoxic effect, @entity2816 increases the risk of severe @entity281 in @entity1 with @entity1582 . We studied 202 @entity1 who received regimens containing @entity2816 in order to assess the time, type, outcome, and factors affecting development of severe @entity281 , role of antibiotic prophylaxis, and effect of severe @entity281 on final outcome. Thirty-eight @entity1 (19%) developed a severe @entity281 early during induction therapy and most @entity281 were @entity55 . Only one @entity1 died due to @entity326 during @entity1398 . No significant differences were reported in terms of progression-free survival (PFS) and overall survival (OS) between @entity1 developing a severe @entity281 and those who did not. Multivariate analysis determined a monoclonal component >3 g/dL and platelets <130,000/ L as factors associated with increased risk of severe @entity281 . Primary antibiotic prophylaxis significantly decreased the probability of severe @entity281 only in @entity1 having both the above risk factors. @entity1 with @entity1582 receiving @entity2816 combinations with high @entity5 burden are at high risk of developing severe @entity281 and require primary antibiotic prophylaxis, whereas in other @entity1 it is questionable. However, @entity1 final outcome was not affected by @entity281 development.
